Stockscreener 앱 받기
2.36
1.67%
-0.04
전일 마감가:
$2.40
열려 있는:
$2.39
하루 거래량:
262.01K
Relative Volume:
1.25
시가총액:
$78.04M
수익:
-
순이익/손실:
$-32.94M
주가수익비율:
-2.1261
EPS:
-1.11
순현금흐름:
$-24.95M
1주 성능:
+18.59%
1개월 성능:
-17.48%
6개월 성능:
-49.89%
1년 성능:
-48.42%
1일 변동 폭
$2.36
$2.48
1주일 범위
$1.96
$2.63
52주 변동 폭
$1.84
$5.59
Achieve Life Sciences Inc Stock (ACHV) Company Profile
명칭
Achieve Life Sciences Inc
전화
425-686-1500
주소
22722 29TH DR. SE, SEATTLE, BC
ACHV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
2.36 | 78.04M | 0 | -32.94M | -24.95M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
| 2024-09-27 | 개시 | Raymond James | Strong Buy |
| 2023-05-10 | 재확인 | Maxim Group | Buy |
| 2021-06-23 | 개시 | Oppenheimer | Outperform |
Achieve Life Sciences Inc 주식(ACHV)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
Here are Rogue Funds Updates on Achieve Life Sciences (ACHV) - MSN
LPL Financial LLC Has $693,000 Stock Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
Achieve Life Sciences announces publication of results from Phase 3 ORCA-3 trial - Yahoo Finance
Cytisinicline shows promise for smoking cessation By Investing.com - Investing.com South Africa
Achieve Life Sciences Expects to File New Drug Application in US for Smoking Cessation Medication - marketscreener.com
Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine | ACHV Stock News - GuruFocus
Achieve Life Sciences (ACHV) Confirms Cytisinicline Efficacy in Phase 3 ORCA-3 Trial | ACHV Stock News - GuruFocus
Cytisinicline’s FDA Path Ignites ACHV Stock: Could This Biotech Gem Soar on Smoking and Vaping Cessation Breakthroughs? - Own Snap
Achieve Life Sciences Announces Cytisinicline Phase 3 - GlobeNewswire
Breakthrough Smoking Cessation Drug Outperforms Existing Treatments in Major Phase 3 Trial, JAMA Reports - Stock Titan
157,519 Shares in Achieve Life Sciences, Inc. (NASDAQ:ACHV) Purchased by Raymond James Financial Inc. - MarketBeat
Raymond James Financial Inc. Invests $554,000 in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
ACHV Stock Touches 52-Week Low at $2.5 Amid Market Challenges - Investing.com UK
ACHIEVE LIFE SCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Contrasting Achieve Life Sciences (NASDAQ:ACHV) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Achieve Life Sciences (ACHV) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Insider Buying: Mark Oki Acquires Shares of Achieve Life Sciences Inc (ACHV) - GuruFocus
Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory - MSN
Achieve Life Sciences CEO Richard Stewart purchases $28,598 in stock - Investing.com India
Achieve Life Sciences CFO Mark Oki buys $28,887 in stock - Investing.com India
Achieve Life Sciences (ACHV) Expected to Announce Quarterly Earnings on Thursday - Defense World
Achieve Life Sciences Executives Acquire Shares - TradingView
Achieve Life Sciences CFO Mark Oki buys $28,887 in stock By Investing.com - Investing.com UK
Achieve Life Sciences CEO Richard Stewart purchases $28,598 in stock By Investing.com - Investing.com UK
Achieve Life Sciences: Promising Clinical Progress and Strategic Leadership Enhancements Justify Buy Rating - TipRanks
ACHV stock touches 52-week low at $2.81 amid market challenges - Investing.com India
Achieve Life Sciences (NASDAQ:ACHV) Announces Earnings Results - MarketBeat
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2024 Earnings Call Transcript - Insider Monkey
ACHV: 2Q:25 NDA Submission - Yahoo Finance
Achieve Life Sciences Inc (ACHV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo
Achieve Life Sciences Reports 2024 Financial Results - TipRanks
Achieve Life Sciences misses Q4 earnings, shares fall By Investing.com - Investing.com South Africa
Achieve Life Sciences misses Q4 earnings, shares fall - Investing.com
Earnings call transcript: Achieve Life Sciences Q4 2024 sees slight EPS miss By Investing.com - Investing.com South Africa
Earnings call transcript: Achieve Life Sciences Q4 2024 sees slight EPS miss - Investing.com
Achieve Life Sciences Q4 Loss Widens - Nasdaq
Achieve Life Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program - The Manila Times
ACHIEVE LIFE SCIENCES Earnings Results: $ACHV Reports Quarterly Earnings - Nasdaq
ACHIEVE LIFE SCIENCES, INC. SEC 10-K Report - TradingView
Achieve Life Sciences Announces Planned NDA Submission for Cytisinicline Targeting End of Q2 2025 - Nasdaq
Achieve Life Sciences Reports Financial Results for Fourth - GlobeNewswire
Achieve Life Sciences Hits Major FDA Milestone as Q4 Results Show $34.4M Cash Position - StockTitan
Earnings Scheduled For March 11, 2025 - Benzinga
SBI Securities Co. Ltd. Purchases New Shares in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
Achieve Life Sciences (ACHV) Projected to Post Earnings on Tuesday - Defense World
Can This Smoking Cessation Drug Developer Disrupt a $20B Market? Key Presentation Coming - StockTitan
Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference - The Manila Times
Achieve Life Sciences Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025 - The Manila Times
Achieve Life Sciences Inc (ACHV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):